“We are extremely excited to welcome Kelly to Lumicell. Kelly was chosen as CEO for her passion for innovation, ability to optimize business strategy, and her overarching desire to make the Lumicell technology available to patients around the globe. With over 25 years of experience in the medical device field, the Board is confident in her ability to lead Lumicell on their mission to change the landscape of cancer surgery,” board chair Dr. Andrey Zarur said in a prepared statement.
The company said it also completed a $13.5 million Series C financing round, saying that with the funding and newly appointed CEO, the company is on track to launch a pivotal trial of its tech in breast cancer this year and engage in the development of additional cancer applications.
“Our team at Lumicell is developing a truly revolutionary intraoperative margin assessment system that gives surgeons real-time visual feedback of residual cancer in the tumor bed. I am honored to lead this team as we strive to greatly improve surgical outcomes and possibly remove the need for repeat cancer surgeries,” CEO Kelly Londy said in a press release.
Cerner co-founder and CEO Neal Patterson passed away last week from complications related to cancer.
Co-founder and vice chair Cliff Illig will act as board chair and interim CEO, the Kansas City, Mo.-based company said.
“This is a profound loss. Neal and I have been partners and collaborators for nearly 40 years, and friends for longer than that. Neal loved waking up every morning at the intersection of health care and IT. His entrepreneurial passion for using IT as a lever to eliminate error, variance, delay, waste and friction changed our industry. One of Neal’s enduring ambitions for Cerner was to build a visionary company, not just a company with a visionary. He has done that. We have what I believe is the best management team in health IT, and we have associates who think as much about the future as they do the present. As a result, Cerner is well-positioned to have a pioneering impact on the provision of health care in the years to come,” Illig said in a press release.
Cerner said its board of directors has had a longstanding succession plan in place and that its search for a new CEO is near completion.
Bourque joined Analogic in 2014 as a VP and corporate controller, and served as the company’s interim CFO from April to November in 2015.
Prior to his time at Analogic, Bourque held a position as finance VP and corporate controller at Axcelis Technology, and acted as corporate accounting director at Charles River Laboratories before that.
“Through his roles at Analogic, Mike has demonstrated the ability to lead our finance organization and an in-depth knowledge of our business. We are confident in Mike’s financial leadership as we position Analogic for renewed success. I would like to thank Mark for his service to Analogic and as an integral member of our senior leadership team. We wish him the very best,” prez & CEO Fred Parks said in a prepared statement.
Cutera (NSDQ:CUTR) said last week it engaged Sandra Gardiner as its consultant chief financial officer as it searchers for a permanent successor to Ronald Santilli, who will be leaving the company after 3 months to assist in a transition.
“Once again, I want to thank Ron for his many contributions over the years here at Cutera. His passion and vision played a large part in the Company’s success, and he will be missed. We appreciate his assistance as we transition the CFO role. We’re delighted to welcome Sandy to Cutera and to our executive leadership team as our consultant CFO. Sandy is equipped with a strong healthcare and device background, coupled with the financial acumen and acuity to manage our financial strategy as we conduct our search for a permanent CFO. I previously worked with Sandy and know she will help drive performance, expand our portfolio, and manage our financial architecture in a sustainable manner,” CEO James Reinstein said in a prepared statement.
Prior to joining Cutera, Gardiner served as finance VP and CFO of Tria Beauty. Gardiner has also served as CFO of Vermillion, Lipid Sciences, Asante Solutions, Aptus Endosystems and Ventus, the company said.
“I am thrilled to be joining the exceptional team at Cutera. We share a passion for innovation and great products that enhance people’s lives, while focusing on growth that will lead us to even greater success as a company,” Ms. Gardiner said in a prepared statement.
“We are excited to have Sam joining us again at AtriCure. He is well recognized as a creative, pragmatic and patient centric innovator with an eye towards bringing high quality products to market efficiently. Additionally, he obviously knows the company well, having served here previously, and he brings a wealth of experience in the Afib space and a deep understanding of the close link between product development and operations. Now is an excellent time to bring him on as we look to continue to scale our organization to support our growth objectives,” prez & CEO Mike Carrel said in a prepared statement.
“I am thrilled to be joining AtriCure at such an exciting time in the company’s evolution. The company has not only done a great job of bringing new technologies to market over the past several years, it has scaled operations without any compromise in the quality standards that have always been integral to its culture. With a broad portfolio of products, and an exciting pipeline, the company is well positioned to build on its leadership position in the treatment of persistent and long-standing persistent Afib,” Privitera said in a press release.